^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Kymriah (tisagenlecleucel-T)

    i
    Other names: CART 19, CTL019, autologous T cells loaded with a lentiviral vector expressing CART-19, autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR Zeta and 4-1 BB co-stimulatory domains, LG-740, CART 019, anti-CD19-CAR retroviral vector-transduced autologous T cells, CART-19, anti-CD19-CAR retroviral vector-transduced autologous T cells, CTL-019, Tisa-cel
    Company:
    Novartis, University of Pennsylvania
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs: